Literature DB >> 2338198

Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease.

M K Porayko1, R H Wiesner, N F LaRusso, J Ludwig, R L MacCarty, B L Steiner, C K Twomey, A R Zinsmeister.   

Abstract

We identified and analyzed 45 patients with asymptomatic primary sclerosing cholangitis to better understand the natural history of this disease. Disease progression was monitored at regular intervals for the development of symptoms and physical signs as well as changes in liver biochemistry, cholangiography, and liver histology. During a median follow-up of 75.2 mo, 34 patients (76%) had evidence of disease progression. Fourteen patients (31%) developed liver failure which resulted in death or referral for liver transplantation. For patients with primary sclerosing cholangitis, survival curves computed using the Kaplan-Meier method were significantly worse than expected when compared to age-, sex-, and race-specific survival rates for the United States north central population (p less than 0.001). These findings indicate that primary sclerosing cholangitis is generally a progressive disease with considerable morbidity and mortality even when detected before the onset of symptoms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338198     DOI: 10.1016/0016-5085(90)91096-o

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  25 in total

1.  Asymptomatic primary sclerosing cholangitis with marked hepatic fibrosis.

Authors:  H Kawai; Y Aoyagi; M Nomoto; H Takizawa; Y Suzuki; A Hama; T Suda; T Takahashi; H Asakura
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

Review 2.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

3.  Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies.

Authors:  Allyson K Martínez; Luca Maroni; Marco Marzioni; Syed T Ahmed; Mena Milad; Debolina Ray; Gianfranco Alpini; Shannon S Glaser
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

Review 4.  Primary sclerosing cholangitis--approach to diagnosis.

Authors:  Ian L Steele; Cynthia Levy; Keith D Lindor
Journal:  MedGenMed       Date:  2007-04-25

Review 5.  Aetiology and natural history of primary sclerosing cholangitis--a decade of progress?

Authors:  R W Chapman
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

Review 6.  The evolution of natural history of primary sclerosing cholangitis.

Authors:  Will R Takakura; James H Tabibian; Christopher L Bowlus
Journal:  Curr Opin Gastroenterol       Date:  2017-03       Impact factor: 3.287

7.  Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study.

Authors:  S A Mitchell; M Thyssen; T R Orchard; D P Jewell; K A Fleming; R W Chapman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 8.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

9.  Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.

Authors:  B Christensen; D Micic; P R Gibson; A Yarur; E Bellaguarda; P Corsello; J N Gaetano; J Kinnucan; V L Rao; S Reddy; S Singh; J Pekow; D T Rubin
Journal:  Aliment Pharmacol Ther       Date:  2018-01-29       Impact factor: 8.171

10.  Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis.

Authors:  K M Abu-Elmagd; M Malinchoc; E R Dickson; J J Fung; P A Murtaugh; A L Langworthy; A J Demetris; R A Krom; D H Van Thiel; T E Starzl
Journal:  Surg Gynecol Obstet       Date:  1993-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.